Syngenta revives Hong Kong IPO discussions aiming at H2 2026 after double-digit growth in biologicals

Syngenta Group is reconsidering a Hong Kong initial public offering for the second half of 2026, supported by double-digit growth in its biologicals business and improved profitability as it seeks to revive plans for a major public listing.

Fertilizer Daily reported in March that Syngenta was targeting a Hong Kong IPO that could raise up to USD 10 billion, marking a renewed effort to return the Chinese state-owned agricultural giant to public markets after earlier attempts stalled. Recent developments indicate the company’s operational performance is increasingly aligned with these ambitions.

Syngenta’s biologicals business grew 11% in 2025, outperforming broader crop protection markets, which faced pressure from agrochemical destocking and weaker pricing. Total group sales reached USD 28.4 billion, down 1% year over year. The company is targeting a 20% EBITDA margin by the end of 2026 as it prepares for a possible market debut.

The company was acquired by China National Chemical Corporation (ChemChina) in a USD 43 billion transaction completed in 2017 and was later reorganized under Sinochem Holdings. Syngenta was delisted from the SIX Swiss Exchange in 2018 and has since explored several routes back to public equity markets.

An earlier Hong Kong IPO process was paused in 2024 due to weak investor appetite for large listings and increased scrutiny of Chinese-owned agribusiness companies. The renewed IPO discussions reflect growing confidence within Syngenta and its parent company that improved earnings and greater exposure to biological crop protection technologies could support a stronger valuation in Asian capital markets.

Sources: AgTech Navigator